NASDAQ:PTCT PTC Therapeutics (PTCT) Stock Forecast, Price & News $42.66 -0.80 (-1.84%) (As of 05/26/2023 08:47 PM ET) Add Compare Share Share Today's Range$42.28▼$44.0250-Day Range$42.66▼$59.1052-Week Range$25.01▼$59.84Volume1.08 million shsAverage Volume820,190 shsMarket Capitalization$3.16 billionP/E RatioN/ADividend YieldN/APrice Target$52.93 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability PTC Therapeutics MarketRank™ ForecastAnalyst RatingHold2.36 Rating ScoreUpside/Downside24.1% Upside$52.93 Price TargetShort InterestBearish7.32% of Shares Sold ShortDividend StrengthN/ASustainability-1.38Upright™ Environmental ScoreNews Sentiment0.07Based on 31 Articles This WeekInsider TradingSelling Shares$7.97 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.21) to ($3.00) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.93 out of 5 starsMedical Sector703rd out of 1,010 stocksPharmaceutical Preparations Industry355th out of 494 stocks 3.2 Analyst's Opinion Consensus RatingPTC Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on 5 buy ratings, 5 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $52.93, PTC Therapeutics has a forecasted upside of 24.1% from its current price of $42.66.Amount of Analyst CoveragePTC Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.32% of the outstanding shares of PTC Therapeutics have been sold short.Short Interest Ratio / Days to CoverPTC Therapeutics has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in PTC Therapeutics has recently increased by 4.02%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldPTC Therapeutics does not currently pay a dividend.Dividend GrowthPTC Therapeutics does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePTC Therapeutics has received a 67.15% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Lipid-lowering medication (C10)", "Glucocorticoids", "Clinical research services for infectious diseases", and "Neuromuscular disorders medication" products. See details.Environmental SustainabilityThe Environmental Impact score for PTC Therapeutics is -1.38. Previous Next 2.3 News and Social Media Coverage News SentimentPTC Therapeutics has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 31 news articles for PTC Therapeutics this week, compared to 5 articles on an average week.MarketBeat Follows7 people have added PTC Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PTC Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,968,916.00 in company stock.Percentage Held by InsidersOnly 5.30% of the stock of PTC Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for PTC Therapeutics are expected to grow in the coming year, from ($4.21) to ($3.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PTC Therapeutics is -5.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PTC Therapeutics is -5.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About PTC Therapeutics (NASDAQ:PTCT) StockPTC Therapeutics, Inc. is a biopharmaceutical company. It engages in discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.Read More Receive PTCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PTCT Stock News HeadlinesMay 28, 2023 | americanbankingnews.comFY2023 EPS Estimates for PTC Therapeutics, Inc. Raised by Cantor Fitzgerald (NASDAQ:PTCT)May 26, 2023 | americanbankingnews.comSVB Leerink Comments on PTC Therapeutics, Inc.'s Q3 2023 Earnings (NASDAQ:PTCT)May 29, 2023 | Stocks To Trade (Ad)Free A.I. Trade Alerts. Up to 15 opportunities a day.Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 26, 2023 | americanbankingnews.comCitigroup Cuts PTC Therapeutics (NASDAQ:PTCT) Price Target to $63.00May 26, 2023 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Stock Rating Reaffirmed by 1-800-FLOWERS.COMMay 25, 2023 | markets.businessinsider.comBank of America Securities Reaffirms Their Sell Rating on PTC Therapeutics (PTCT)May 25, 2023 | msn.comRBC Capital Maintains PTC Therapeutics (PTCT) Sector Perform RecommendationMay 24, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Sarepta Therapeutics (SRPT) and PTC Therapeutics (PTCT)May 29, 2023 | Chaikin Analytics (Ad)Wall Street Legend Who Called AMZN Crash Issues New Sell AlertNow, after years of big gains, he says one popular company's day in the sun is finally coming to an end. You must get off this sinking ship – NOW. 1 million people follow him for his surprisingly accurate predictions. His new sell alert could save your wealth in 2023.May 24, 2023 | markets.businessinsider.com14 Analysts Have This to Say About PTC TherapeuticsMay 24, 2023 | finance.yahoo.comPTC Therapeutics Stock Tumbles: Company Stops Preclinical Gene Therapy Programs After Failed Friedreich's Ataxia StudyMay 24, 2023 | finance.yahoo.comPTC Therapeutics' Barrage Of Bad News Is Good News For Rival Reata Pharmaceuticals — Here's WhyMay 24, 2023 | investorplace.comWhy Is PTC Therapeutics (PTCT) Stock Down 21% Today?May 24, 2023 | americanbankingnews.comCredit Suisse Group Trims PTC Therapeutics (NASDAQ:PTCT) Target Price to $50.00May 24, 2023 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) PT Lowered to $48.00May 24, 2023 | msn.comPTC abandons preclinical gene therapy programs, cuts staff; CFO departsMay 24, 2023 | msn.comPTCT Crashes after Cutting Down on Gene Therapy Programs, CFO DepartureMay 23, 2023 | finance.yahoo.comPTC Therapeutics Announces Strategic Pipeline PrioritizationMay 23, 2023 | finance.yahoo.comPTC Therapeutics Announces Topline Results from Vatiquinone MOVE-FA Registration-Directed TrialMay 22, 2023 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) PT Raised to $43.00 at Bank of AmericaMay 22, 2023 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Given New $70.00 Price Target at CitigroupMay 22, 2023 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Coverage Initiated at StockNews.comMay 20, 2023 | americanbankingnews.comThe Goldman Sachs Group Boosts PTC Therapeutics (NASDAQ:PTCT) Price Target to $37.00May 20, 2023 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) PT Raised to $57.00May 19, 2023 | msn.comUnusual Put Option Trade in PTC Therapeutics (PTCT) Worth $187.00KMay 19, 2023 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Reaches New 1-Year High Following Analyst UpgradeMay 19, 2023 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Given Maintains Rating at VNET GroupSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PTCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PTCT Company Calendar Last Earnings4/27/2023Today5/29/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PTCT CUSIPN/A CIK1070081 Webwww.ptcbio.com Phone(908) 222-7000Fax908-222-7231Employees1,410Year FoundedN/APrice Target and Rating Average Stock Price Forecast$52.93 High Stock Price Forecast$66.00 Low Stock Price Forecast$37.00 Forecasted Upside/Downside+24.1%Consensus RatingHold Rating Score (0-4)2.36 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($7.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-559,020,000.00 Net Margins-74.14% Pretax Margin-77.95% Return on EquityN/A Return on Assets-34.13% Debt Debt-to-Equity RatioN/A Current Ratio1.39 Quick Ratio1.33 Sales & Book Value Annual Sales$698.80 million Price / Sales4.53 Cash FlowN/A Price / Cash FlowN/A Book Value($4.76) per share Price / Book-8.96Miscellaneous Outstanding Shares74,190,000Free Float70,259,000Market Cap$3.16 billion OptionableOptionable Beta0.43 Key ExecutivesMatthew B. KleinPresident, Chief Executive Officer & DirectorEmily HillChief Financial OfficerNeil Gregory AlmsteadChief Technical Operations OfficerEllen WelchChief Scientific OfficerMark Elliott BouldingChief Legal Officer & Executive Vice PresidentKey CompetitorsTG TherapeuticsNASDAQ:TGTXElanco Animal HealthNYSE:ELANPerrigoNYSE:PRGOACADIA PharmaceuticalsNASDAQ:ACADArrowhead PharmaceuticalsNASDAQ:ARWRView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 1,599 shares on 5/26/2023Ownership: 0.018%Putnam Investments LLCSold 12,175 shares on 5/22/2023Ownership: 0.065%JPMorgan Chase & Co.Bought 6,683 shares on 5/18/2023Ownership: 1.171%International Biotechnology Trust PLCSold 51,000 shares on 5/18/2023Ownership: 0.125%New York State Common Retirement FundSold 5,775 shares on 5/18/2023Ownership: 0.095%View All Insider TransactionsView All Institutional Transactions PTCT Stock - Frequently Asked Questions Should I buy or sell PTC Therapeutics stock right now? 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 1 sell rating, 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PTCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PTCT, but not buy additional shares or sell existing shares. View PTCT analyst ratings or view top-rated stocks. What is PTC Therapeutics' stock price forecast for 2023? 11 brokers have issued twelve-month price targets for PTC Therapeutics' shares. Their PTCT share price forecasts range from $37.00 to $66.00. On average, they anticipate the company's stock price to reach $52.93 in the next year. This suggests a possible upside of 24.1% from the stock's current price. View analysts price targets for PTCT or view top-rated stocks among Wall Street analysts. How have PTCT shares performed in 2023? PTC Therapeutics' stock was trading at $38.17 on January 1st, 2023. Since then, PTCT stock has increased by 11.8% and is now trading at $42.66. View the best growth stocks for 2023 here. When is PTC Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our PTCT earnings forecast. How were PTC Therapeutics' earnings last quarter? PTC Therapeutics, Inc. (NASDAQ:PTCT) issued its earnings results on Thursday, April, 27th. The biopharmaceutical company reported ($1.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.64) by $0.24. The biopharmaceutical company earned $220.38 million during the quarter, compared to analyst estimates of $200.48 million. The firm's revenue was up 48.2% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.78) EPS. What ETFs hold PTC Therapeutics' stock? ETFs with the largest weight of PTC Therapeutics (NASDAQ:PTCT) stock in their portfolio include Direxion mRNA ETF (MSGR), iShares Neuroscience and Healthcare ETF (IBRN), Invesco Dynamic Biotechnology & Genome ETF (PBE), MFAM Small-Cap Growth ETF (MFMS), Motley Fool Small-Cap Growth ETF (TMFS), Virtus LifeSci Biotech Products ETF (BBP), Franklin Genomic Advancements ETF (HELX) and Invesco DWA Healthcare Momentum ETF (PTH). What guidance has PTC Therapeutics issued on next quarter's earnings? PTC Therapeutics updated its FY 2023 earnings guidance on Thursday, April, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $940.00M-$1.00 billion, compared to the consensus revenue estimate of $866.89 million. What is Stuart W. Peltz's approval rating as PTC Therapeutics' CEO? 24 employees have rated PTC Therapeutics Chief Executive Officer Stuart W. Peltz on Glassdoor.com. Stuart W. Peltz has an approval rating of 77% among the company's employees. What other stocks do shareholders of PTC Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals (GWPH), Bausch Health Companies (BHC), NVIDIA (NVDA), Cisco Systems (CSCO), Regulus Therapeutics (RGLS), Aduro Biotech (ADRO) and Gilead Sciences (GILD). What is PTC Therapeutics' stock symbol? PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT." Who are PTC Therapeutics' major shareholders? PTC Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include RTW Investments LP (9.56%), Wellington Management Group LLP (9.43%), Armistice Capital LLC (3.94%), State Street Corp (3.92%), Price T Rowe Associates Inc. MD (2.32%) and Macquarie Group Ltd. (2.21%). Insiders that own company stock include Allan Steven Jacobson, Christine Marie Utter, David P Southwell, Dawn Svoronos, Emily Luisa Hill, Emma Reeve, Eric Pauwels, Mark Elliott Boulding, Matthew B Klein, Matthew B Klein, Neil Gregory Almstead, Stephanie Okey and Stuart Walter Peltz. View institutional ownership trends. How do I buy shares of PTC Therapeutics? Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is PTC Therapeutics' stock price today? One share of PTCT stock can currently be purchased for approximately $42.66. How much money does PTC Therapeutics make? PTC Therapeutics (NASDAQ:PTCT) has a market capitalization of $3.16 billion and generates $698.80 million in revenue each year. The biopharmaceutical company earns $-559,020,000.00 in net income (profit) each year or ($7.89) on an earnings per share basis. How many employees does PTC Therapeutics have? The company employs 1,410 workers across the globe. How can I contact PTC Therapeutics? PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The official website for the company is www.ptcbio.com. The biopharmaceutical company can be reached via phone at (908) 222-7000, via email at ehill@ptcbio.com, or via fax at 908-222-7231. This page (NASDAQ:PTCT) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.